Increased blood pressure (BP) in genetic hypertension is usually caused by high activity of sympathetic nervous system (SNS) which is enhanced by central angiotensin II but lowered by central nitric oxide (NO). We have therefore evaluated NO synthase (NOS) activity as well as neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS) protein expression in brainstem and midbrain of adult spontaneously hypertensive rats (SHR) characterized by enhanced sympathetic vasoconstriction. We also studied possible participation of brain NO in antihypertensive effects of chronic captopril treatment of adult SHR. NOS activity was increased in midbrain of SHR compared to Wistar-Kyoto (WKY) rats. This could be ascribed to enhanced iNOS expression, whereas nNOS expression was unchanged and eNOS expression was reduced in this brain region. In contrast, no significant changes of NOS activity were found in brainstem of SHR in which nNOS and iNOS expression was unchanged, but eNOS expression was increased. Chronic captopril administration lowered BP of adult SHR mainly by attenuation of sympathetic tone, whereas the reduction of angiotensin II-dependent vasoconstriction and the decrease of residual BP (amelioration of structural remodeling of resistance vessels) were less important. This treatment did not affect significantly either NOS activity or expression of any NOS isoform in the two brain regions. Our data do not support the hypothesis that altered brain NO formation contributes to sympathetic hyperactivity and high BP of adult SHR with established hypertension.

Institute of Physiology AS CR Charles University Videnska 1083 142 20 Prague 4 Czech Republic

Zobrazit více v PubMed

Proc Natl Acad Sci U S A. 1990 Jan;87(2):682-5 PubMed

Neuron. 1992 Jan;8(1):3-11 PubMed

J Hypertens Suppl. 2002 Jun;20(5):S3-11 PubMed

Hypertension. 1998 Feb;31(2):643-8 PubMed

Annu Rev Neurosci. 1994;17:153-83 PubMed

J Hypertens. 2003 Sep;21(9):1687-94 PubMed

Clin Exp Pharmacol Physiol. 2005 May-Jun;32(5-6):384-93 PubMed

J Pharmacol Exp Ther. 1991 Oct;259(1):52-7 PubMed

Hypertension. 1998 Apr;31(4):1030-4 PubMed

J Hypertens. 2002 May;20(5):945-55 PubMed

J Hypertens. 2001 Mar;19(3):465-73 PubMed

Eur J Pharmacol. 1983 Mar 25;88(2-3):231-40 PubMed

Biochem Pharmacol. 1978;27(20):2379-89 PubMed

Brain Res Mol Brain Res. 2005 Aug 18;138(2):198-204 PubMed

Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):33-43 PubMed

Clin Exp Pharmacol Physiol. 1998 Jun;25(6):474-8 PubMed

Brain Res Brain Res Rev. 1992 Sep-Dec;17(3):227-62 PubMed

J Hypertens. 2001 Feb;19(2):247-54 PubMed

Hypertension. 2002 Oct;40(4):552-9 PubMed

J Cereb Blood Flow Metab. 2003 Mar;23(3):371-80 PubMed

Curr Hypertens Rep. 2002 Apr;4(2):129-35 PubMed

Am J Hypertens. 1996 Mar;9(3):237-41 PubMed

Clin Sci (Lond). 1995 Aug;89(2):177-82 PubMed

J Hypertens. 2005 Sep;23(9):1683-90 PubMed

Clin Exp Pharmacol Physiol. 1997 Jan;24(1):96-101 PubMed

Brain Res Mol Brain Res. 1997 Sep;48(2):291-7 PubMed

Clin Exp Pharmacol Physiol. 2005 May-Jun;32(5-6):440-6 PubMed

Circulation. 2001 Oct 2;104(14 ):1676-81 PubMed

Neuroscience. 1992;46(4):755-84 PubMed

Brain Res Bull. 1988 Feb;20(2):197-201 PubMed

Clin Sci (Lond). 2002 Mar;102(3):269-77 PubMed

J Mol Cell Cardiol. 1997 Dec;29(12):3365-74 PubMed

Clin Exp Pharmacol Physiol. 2005 May-Jun;32(5-6):419-25 PubMed

Br J Pharmacol. 2003 May;139(2):191-202 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 1982 Dec;321(4):309-13 PubMed

Regul Pept. 1999 May 31;81(1-3):1-10 PubMed

Hypertension. 2002 Feb;39(2):275-80 PubMed